Global Companion Diagnostic Technologies Market Companies
- Qiagen LLC
- Roche
- Abbott Laboratories Inc.
- Ventana Medical Systems
- bioMerieux
- Myriad Genetics Inc.
- Resonance Health Ltd.
- Leica Microsystems
- Life Technologies
Recent News:
- The Guardant360 CDx assay, a next-generation sequencing (NGS) test that uses circulating cell-free DNA from peripheral whole blood plasma to identify EGFR mutations in patients with non-small cell lung cancer who may benefit from osimertinib (Tagrisso) therapy, was approved by the Guardant Health, Inc. agency in August 2020. The test is the first liquid biopsy assay that uses NGS technology, according to the FDA.
- The Food and Drug Administration of the United States authorized "FoundationOne CDx" in May 2020 as a companion diagnostic for LYNPARZA, a product of Foundation Medicine Inc. The only CGP (comprehensive genomic profiling) test that has received FDA approval for solid tumors of any kind that incorporates a number of companion diagnostic claims is the recently approved FoundationOne CDx.
- The Food and Drug Administration (FDA) approved Myriad's innovation, "mychoice CDx as a companion diagnostic for Lynparza," in May 2020. It was created with women with ovarian cancer in mind, with the hope that it will assist medical professionals in identifying patients who will benefit from treatment and whose HRD is positive.
- Qiagen introduced the "Therascreen FGFR RGQ RT-PCR Kit" in April 2019. This kit is the first to be approved by the FDA for treating metastatic urothelial cancer and may also be used as a companion diagnostic.